Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
NEW YORK, Feb. 05, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Michigan on behalf of investors who purchased Esperion Therapeutics, Inc. (NASDAQ:ESPR) securities between August 18, 2015 and September 28, 2015.
Click here to learn about the case: http://docs.wongesq.com/ESPR-Info-Request-Form-1062. There is no cost or obligation to you.
The complaint alleges that Defendants issued false and misleading statements regarding the Company’s business and prospects, including that there was no clear path to approval for ETC-1002, the Company’s lead product candidate designed to lower LDL-cholesterol levels, and that the FDA had encouraged the Company to initiate a cardiovascular outcomes trial (“CVOT”) and that completion of a CVOT could be necessary prior to approval of ETC-1002.
On August 17, 2015, Esperion reported to investors material events from an August 2015 meeting with the FDA; the Company stated that during the meeting it was informed by the FDA that the Company would not have to complete a CVOT to gain approval of ETC-1002. Then in a September 28, 2015 news release the Company noted that the FDA had actually “encouraged the Company to initiate a cardiovascular outcomes trial promptly” and it may be necessary to have a completed CVOT prior to approval.
If you suffered a loss in Esperion Therapeutics you have until March 14, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/ESPR-Info-Request-Form-1062.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
